Anti-Cbl proto-oncogene antibodies are used for the immunodetection of the protein encoded by the CBL gene. In humans, the canonical protein has a reported length of 906 amino acid residues and a mass of 99.6 kDa. Its subcellular localization is in the cell membrane, Golgi, and cytoplasm. It is a reported adaptor protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Post-translational modifications have been described, including ubiquitination and phosphorylation. Other names for this target antigen include CBL2, FRA11B, NSLL, RNF55, E3 ubiquitin-protein ligase CBL, and C-CBL. Gene orthologs have been identified in the mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken species. Over 190 citations in the literature describe the use of Cbl proto-oncogene antibodies in research. Western Blot is a widely used application for these antibodies. ELISA, Immunofluorescence, and Immunohistochemistry are also common applications.